Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

By T. Browder, C. Butterfield, B. Kräling, B. Shi, B. Marshall, M. O’Reilly, J. Folkman. Cancer Research, 2000

1,658 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/f0860a0dad6791dbf5b927baa9525b375b611eaf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. N. Ferrara
2. D. Hanahan
3. G. Bergers
4. H. Gerber
5. Rakesh K. Jain
6. E. Bergsland
7. B. Kamen
8. J. Joyce

Citations in the corpus

• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. (2003, unknown): “Combination of either class of inhibitor with an antiangiogenic, “metronomic” chemotherapy regimen (12, 15, 16) produced stable disease or modest regression of such tumors (13), encouraging the proposition that combinatorial targeted therapies might be a key to achieving late-stage efficacy with a V”
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (2000, methodology): “, who used low-dose cyclophosphamide therapy (26), we found evidence, in our case using the Matrigel plug assay, that continuous low-dose vinblastine administration can cause a direct antiangiogenic effect in vivo.”
• NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES (2011, unknown): “Recent observations support the notion that this antivascular effect of chemotherapy is maximized when drugs are administered at lower doses on a continuous schedule, without significant interruption, referred to as metronomic chemotherapy (38, 164).”
• Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. (2000, background): “(9) grew cyclophosphamide-resistant tumors (Lewis lung carcinoma and EMT-6 breast carcinoma) in immunocompetent mice to focus more specifically on the effects of a cytotoxic drug on tumor endothelium under different dosing schedule.”
• The anti-angiogenic basis of metronomic chemotherapy (2004, background): “Similarly, Browder et al. tested the weekly low-dose cyclophosphamide regimen using a CORNEAL MICROPOCKET ASSAY to show that this metronomic therapy protocol inhibited angiogenesis 22 .”
• Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. (2005, background): “(47), paclitaxel (48), and doxorubicin (49), have antiangiogenic”